From Courtroom to Lab: Bayer Navigates a Pivotal Summer as Three Catalysts Converge

Bayer shares trade flat near €36, caught between legal risks from 65,000 Roundup lawsuits and positive FDA approvals. Supreme Court decision expected by June.

Bayer’s stock is treading water near €36 – a level that reflects a market caught between genuine operational progress and an existential legal overhang. The shares have barely budged despite a string of positive developments from the company’s labs, because the real prize lies in a Washington courtroom. With a Supreme Court ruling on the glyphosate saga expected by the end of June – and possibly stretching into late July – investors are placing their bets on a judicial coin toss.

The court’s decision in Monsanto v. Durnell will determine whether state-law failure-to-warn claims against pesticide makers can proceed when the U.S. Environmental Protection Agency (EPA) has not mandated such warnings. The Trump administration sided with Monsanto during oral arguments on April 27, requesting its own time to argue. Should the justices rule in Bayer’s favor, the bulk of the roughly 65,000 remaining Roundup lawsuits would be blocked. The company has already paid more than $10 billion in settlements. A negative outcome, by contrast, could send the stock back toward its 52-week low of €25.09.

While the market waits, a separate legal battle is playing out behind the scenes. Bayer is fighting to salvage its $7.25 billion Missouri settlement, which 13 objectors are challenging. They argue the deal is a coordinated maneuver between Monsanto and plaintiffs’ lawyers designed to move the case from state court to federal court. The U.S. Judicial Panel on Multidistrict Litigation has issued a conditional transfer order, potentially sending the matter to Judge Vince Chhabria in California – who has already handled numerous Roundup cases. Chhabria, however, has said he does not see himself as the appropriate authority to oversee the settlement. Barclays analysts describe the situation as procedural complexity with timing risk, warning that the fairness hearing scheduled for July could be delayed as long as the jurisdictional question remains unresolved.

Against this legal backdrop, Bayer’s pharmaceutical pipeline is quietly delivering. The FDA recently approved AMBELVIST, an MRI contrast agent that uses significantly less gadolinium than conventional products. The company is also pursuing a breakthrough in agriculture: it has filed for regulatory approval of icafolin-methyl in the European Union, the United States, Brazil and Canada. Bayer describes the molecule as the first new mode of action for post-emergent broadacre weed control in more than three decades. Commercial launch is expected from 2028, starting in Brazil, with estimated peak sales of around €750 million.

Yet none of this has been enough to lift the stock out of its rut. Shares recently changed hands at €36.11, barely above the 200-day moving average – calculated as €36.07 by one measure and €36.03 by another. The relative strength index stands at a neutral 46.8. From the 52-week high of €49.93, the stock remains roughly 28% lower, while a February high sits about 27% above current levels.

The operational challenges go beyond litigation. Bayer is in the midst of a radical corporate overhaul, aiming to cut costs by €2 billion by the end of 2026 through deep job cuts, especially in management. Revenue edged up to €46 billion, but a multibillion-euro special charge for legal disputes dragged net income deep into the red. Net debt remains a punishing €30 billion, sapping the financial flexibility that Bayer needs to invest in growth.

That debt burden is what keeps the breakup debate simmering. Management officially opposes a split, but the argument goes that this stance would collapse if the glyphosate cloud lifted. A spin-off of Consumer Health could slash liabilities, while a more radical separation of pharma and agriculture would create two focused entities – something many investors are demanding. A favorable Supreme Court ruling would almost certainly reignite those calls.

For now, Bayer’s shares are pricing in very little. Investors are effectively making a binary bet on the outcome in Washington. A positive verdict could unlock both financial freedom and structural change. A negative one risks dragging the stock back down to levels not seen in over a year. The next few weeks will decide which path the company takes.